Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Published in Clinical Imaging, the responses indicate that Trump administration policies have made it more difficult to acquire funding and collaborate with other researchers.
"I wasn’t expecting these results among women in this lower age group, because we usually see increased risk for heart disease among older women," one cardiologist said. "It was definitely surprising.”
There were no statistical differences in overall complication rates between the traditional and expedited groups, but there were marked savings and shorter hospital stays.
The past four years have witnessed major advancements in medical science’s drive to unravel the complexities of the human immune system. We have the COVID-19 pandemic to thank for much of the progress.
